NovAccess Global, Inc. to Present at the 2021 Global Congress of the Prestigious Society for Brain Mapping and Therapeutics


CLEVELAND, OH / ACCESSWIRE / July 8, 2021 / NovAccess Global, Inc. (OTC PINK: XSNX) announced that it has been invited to present at the Society for Brain Mapping and Therapeutics (SBMT) 18e World Congress, which will take place July 8-11, 2021. The conference aims to break down the boundaries of science, technology, medicine, art and health policy. The event, known as “The Oscars Equivalent for Neuroscience,” and a trade show will be held at the Convention Center in Los Angeles, California.

The 17th / 18th Annual SBMT World Congress will bring together physicians, scientists, policy makers, funding bodies and industry to advance the advancements and applications of brain and spinal cord mapping and guided therapies by the image (operative and non-operative). SBMT is a non-profit company organized to encourage fundamental and clinical scientists and engineers interested in the fields of brain mapping and therapeutics to improve the diagnosis, treatment and rehabilitation of patients with neurological disorders.

Dr Chris Wheeler. The president of StemVax Therapeutics, Inc., a global NovAccess company, will co-chair a presentation titled “Interactions and Inflammation of the Brain and Immune System” from 3:30 pm to 5:00 pm on Friday, July 9. The presentation will incorporate industry advancements and specific information on the progress of NovAccess Global. Dr Wheeler and CEO Dr Dwain Irvin will also participate in individual and group meetings throughout the conference.

For more information, please visit

About NovAccess Global
NovAccess Global is a biomedical company that accelerates cancer diagnosis and therapy. Our goal is to discover, develop and bring to the market new and innovative drugs and medical devices to improve the quality of care for cancer and neurological patients.

NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient’s immune response against brain tumors. Our company has a novel immunotherapeutic approach to treat brain tumor patients with glioblastoma multiforme, the most common adult brain tumor with a median survival of 15 months after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of Toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient’s tumor. Our platform’s technology focuses on enhancing the patient’s immune cells to fight their unique cancer using antigens specific to the patient’s tumor. The company has a cancer vaccine, which is a drug that stimulates or restores the ability of the immune system to fight existing cancer by strengthening the body’s natural defenses against cancer cells. This is a significant technology that could dramatically improve the quality of life and the prognosis for the many people who suffer from brain tumors. For more information, please visit

Forward-looking statement
This email and its attachments contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results or strategies and are usually preceded by words such as “may”, ” future “,” plan “or” planned “,” will “or” should “,” expected “,” anticipate “,” draft “,” possibly “or” planned “. You are cautioned that these statements are subject to a multitude of risks and uncertainties which could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ. substantially from those projected. in forward-looking statements due to various factors and other risks identified in the Company’s disclosures or filings with the Securities Exchange Commission and / or OTC Markets, Inc. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess, Inc. are inherently volatile and risky and no investor should buy that stock unless they can afford the loss of their entire investment. The Company disclaims any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Broker and analyst contact:
Chesapeake Group
+1 (410) 825-3930
[email protected]

Investor Relations Contact:
Satya chillara
Darrow Partners
(510) 396-2776
[email protected]

SOURCE: NovAccess Global Inc.

See the source version on


Leave a Reply

Your email address will not be published.